2 completed, 1 recruiting. 2 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Recruiting 1 |
| Phase 4 | 1 | Completed 1 |
Follow Common Variable Immunodeficiency (CVID): new trials by email Literature Review of Common Variable Immunodeficiency (CVID) trials Research Report on Common Variable Immunodeficiency (CVID)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD) Hematopoietic stem cell transplant (HSCT) - Common Variable Immunodeficiency (CVID), Primary Immune Regulatory Disorder | Phase 2 | Recruiting | Paul Szabolcs | 25 | 2026-05-04 | 2026-05-15 |
| Leniolisib for Immune Dysregulation in CVID Leniolisib - Common Variable Immunodeficiency (CVID) | Phase 2 | Completed | Pharming Technologies B.V. | 27 | 2025-02-12 | 2026-09-18 |
| The Rifaximin Study in CVID Rifaximin - Common Variable Immunodeficiency (CVID) | Phase 4 | Completed | Oslo University Hospital | 40 | 2013-10-01 | 2015-04-24 |
Common Variable Immunodeficiency (3) · DiGeorge Syndrome (1) · Granulomatous Disease, Chronic (1) · Hyper-IgM Immunodeficiency Syndrome (1) · Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked Syndrome (1) · Intestinal Diseases (1) · Severe Combined Immunodeficiency (1)
Immune System Diseases (3) · Immunologic Deficiency Syndromes (3) · 22q11 Deletion Syndrome (1) · Abnormalities, Multiple (1) · Blood Protein Disorders (1) · Cardiovascular Abnormalities (1) · Cardiovascular Diseases (1) · Chromosome Disorders (1) · Chronic Disease (1) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Craniofacial Abnormalities (1) · DNA Repair-Deficiency Disorders (1) · Digestive System Diseases (1) · Disease Attributes (1)
Rifaximin (1) · Stem Cell Transplantation (1) · leniolisib (1)
Oslo University Hospital (1) · Paul Szabolcs (1) · Pharming Technologies B.V. (1)
United States (2) · Norway (1) · Spain (1) · United Kingdom (1)
Borre Fevang, MD, Phd (1) · Paul Szabolcs, MD (1)